Screening and Evaluation In Vivo

  • John F. Ryley
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 96)


If, as has been suggested, screening in vitro can be misleading and unreliable, it is even more important that in vivo screens should be relevant and that they should be able to cope with large numbers of compounds in restricted quantity. Although topical activity may be achievable in a new compound, a profusion of topical antifungals of differing chemical types is already available. As the current medical need is rather for safer and more effective drugs which can be given by mouth or by injection, the following discussion will be mostly concerned with systemic activity. The purpose of the screen is firstly to detect in vivo antifungal activity and then to indicate whether or not that activity is worth further investigation (as systemic activity in vivo is rare, it will be worth further investigation!). Because of varying fungal susceptibilities, compounded by the distribution patterns of compounds in the body and the different sites of fungal location, some indication of the effective spectrum of activity is desirable; e.g. although Candida albicans is basically susceptible to amphotericin B and systemic infections do show a response to treatment, vaginal ones do not. Other compounds will be basically narrow in their spectrum of activity, e.g. griseofulvin and terbinafine only have utility against dermatophytes, 5-fluorocytosine only against yeasts and cilofungin (LY 121019) only against two species of Candida. As there appears to be commercial viability in narrow spectrum antifungal agents as well as a medical need, the screen should be able to detect both types of activity. Extrapolation from mice to humans is never easy, and so comparison with already established antifungals will be important in assessing the possible significance of activity detected in the screen.


Candida Albicans Antimicrob Agent Cryptococcal Meningitis Minimum Effective Dose Fungal Count 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ackerbauer H, Meingassner JG, Mieth H (1985) Experimental renal infection with Aspergillus fumigatus in mice: a chemotherapeutic model of an organic mycosis. Mykosen 2–8: 244–250PubMedGoogle Scholar
  2. Allen AM, King RD (1978) Occlusion, carbon dioxide, and fungal skin infections. Lancet I: 360–362Google Scholar
  3. Fromtling RA, Abruzzo GK, Ruiz A (1988) Cryptococcus neoformans: a central nervous system isolate from an AIDS patient that is rhinotropic in a normal mouse model. Mycopathologia 102: 79–86Google Scholar
  4. Galgiani JN, Van Wyck DB (1984) Ornithyl amphotericin methyl ester treatment of experimental candidiasis in rats. Antimicrob Agents Chemother 26: 108–109PubMedGoogle Scholar
  5. Gentles JC (1958) Experimental ringworm in guinea pigs: oral treatment with griseofulvin. Nature 182: 476–477PubMedCrossRefGoogle Scholar
  6. Graybill JR, Ahrens J (1984) R 51211 (itraconazole) therapy of murine cryptococcosis. Sabouraudia: J Med Vet Mycol 22: 445–453CrossRefGoogle Scholar
  7. Graybill JR, Ahrens J (1985) Itraconazole treatment of murine aspergillosis. Sabouraudia: J Med Vet Mycol 23: 219–223CrossRefGoogle Scholar
  8. Graybill JR, Ahrens J, Nealon T, Paque R (1983a) Pulmonary cryptococcosis in the rat. Am Rev Resp Dis 127: 636–640PubMedGoogle Scholar
  9. Graybill JR, Kaster SR, Drutz DJ (1983b) Comparative activities of Bay n 7133, ICI 153,066, and ketoconazole in murine cryptococcosis. Antimicrob Agents Chemother 24: 829–834PubMedGoogle Scholar
  10. Graybill JR, Kaster SR, Drutz DJ (1983c) Treatment of experimental murine aspergillosis with BAY n 7133. J Infect Dis 148: 898–906PubMedCrossRefGoogle Scholar
  11. Graybill JR, Palou E, Ahrens J (1986a) Treatment of murine histoplasmosis with UR 49,858 (fluconazole). Am Rev Resp Dis 134: 768–770PubMedGoogle Scholar
  12. Graybill JR, Sun SH, Ahrens J (1986b) Treatment of murine coccidioidal meningitis with fluconazole (UR 49,858). J Med Vet Mycol 24: 113–119PubMedCrossRefGoogle Scholar
  13. Hare RS, Loebenberg D (1988) Animal models in the search for antifungal agents. ASM News 54: 235–239Google Scholar
  14. Herrera C, Guentzel MN (1982) Mice with persistent gastrointestinal Candida albicans as a model for antifungal therapy. Antimicrob Agents Chemother 21: 51–53PubMedGoogle Scholar
  15. Hughes CE, Peterson LR, Beggs WH, Gerding DN (1986) Ketoconazole and flucytosine alone and in combination against Candida spp. in a neutropenic site in rabbits. J Antimicrob Chemother 18: 65–72PubMedCrossRefGoogle Scholar
  16. Kerbs S, Allen AM (1978) Effect of occlusion on Trichophyton mentagrophytes infections in guinea pigs. J Invest Dermatol 71: 301–304PubMedCrossRefGoogle Scholar
  17. Kobayashi GS, Travis S, Medoff G (1986) Comparison of the in vitro and in vivo activity of the bistriazole derivative UK 49,858 with that of amphotericin B against Histoplasma capsulatum. Antimicrob Agents Chemother 29: 660–662PubMedGoogle Scholar
  18. Krause M, Schaffner A (1988) Comparison of immune mechanisms against Candida albicans in models of localized and systemic infection in mice. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles, Abstr 1287, p 341Google Scholar
  19. Lefler E, Brummer E, McEwen JG, Hoyos GL, Restrepo A, Stevens DA (1985a) Study of current and new drugs in a murine model of acute paracoccidioidomy¬cosis. Amer J Trop Med Hyg 34: 134–140Google Scholar
  20. Lefler E, Brummer E, Perlman AM, Stevens DA (1985b) Activities of the modified polyene jV-D-ornithyl amphotericin methyl ester and the azoles ICI 153,066, Bay n 7133, and Bay 1 9139 compared with those of amphotericin B and ketoconazole in the therapy of experimental blastomycosis. Antimicrob Agents Chemother 27: 363–366PubMedGoogle Scholar
  21. Levine HB (1984) A direct comparison of oral treatment with BAY-n-7133, BAY-1- 9139 and ketoconazole in experimental murine coccidioidomycosis. Sabouraudia: J Med Vet Mycol 22: 37–46CrossRefGoogle Scholar
  22. Martin MV (1989) A comparison of fluconazole and ketoconazole in the treatment of rat palatal candidosis. J Med Vet Mycol 27: 63–70PubMedCrossRefGoogle Scholar
  23. Novick LN, Tapia L, Bottone EJ (1987) Invasive Trichophyton rubrum infection in an immunocompromised host. Am J Med 82: 321–325PubMedCrossRefGoogle Scholar
  24. Perfect JR, Durack DT (1985) Comparison of amphotericin B and iV-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis. Antimicrob Agents Chemother 28: 751–755PubMedGoogle Scholar
  25. Perfect JR, Lang SDR, Durack DT (1980) Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol 101: 117–194Google Scholar
  26. Perfect JR, Savani DV, Durack DT (1986) Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and Candida pyelonephritis in rabbits. Antimicrob Agents Chemother 29: 579–583PubMedGoogle Scholar
  27. Petranyi G, Leitner I, Mieth H (1982) The ‘hair root invasion test’, a semi-quantitative method for experimental evaluation of antimycotics in guinea pigs. Sabouraudia 20: 101–108PubMedCrossRefGoogle Scholar
  28. Polak A (1984a) Experimental infection of mice by Fonsecaea pedrosoi and Wangiella dermatitidis. Sabouraudia: J Med Vet Mycol 22: 167–169CrossRefGoogle Scholar
  29. Polak A (1984b) Antimycotic therapy of experimental infections caused by dematiaceous fungi. Sabouraudia: J Med Vet Mycol 22: 279–289CrossRefGoogle Scholar
  30. Polak A (1987) Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy 33: 381–395PubMedCrossRefGoogle Scholar
  31. Polak A, Dixon DM (1986) Fungistatic and fungicidal effects of amphotericin B, ketoconazole and fluconazole (UK 49,858) against Histoplasma capsulatum in vitro and in vivo. Mykosen 30: 186–194Google Scholar
  32. Polak A, Dixon DM (1988) Chemotherapeutic activity in a mouse model of cryptococcosis with cutaneous and nasal involvement. Mycoses 31: 501–507PubMedCrossRefGoogle Scholar
  33. Polak A, Schaffner A (1989) A new experimental model of localized candidosis for the study of antifungal chemotherapy. Mycoses 32: 398–404PubMedCrossRefGoogle Scholar
  34. Ray TL (1985) Animal models of experimental Candida infections of the skin. In: Maibach HI, Lowe NJ (eds) Models in dermatology, vol I. Karger, Basel, pp 41–50Google Scholar
  35. Richardson K, Brammer KW, Marriott MS, Troke PF (1985) Activity of UK 49,858, a bistriazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother 27: 832–835PubMedGoogle Scholar
  36. Russell C, Jones JH, Gibbs ACC (1976) The carriage of Candida albicans in the mouths of rats treated with tetracycline briefly or for a prolonged period. Mycopathologia 58: 125–129PubMedCrossRefGoogle Scholar
  37. Ryley JF, McGregor S (1986) Quantification of vaginal Candida albicans infections in rodents. J Med Vet Mycol 24: 455–460PubMedCrossRefGoogle Scholar
  38. Ryley JF, McGregor S (1988) A multi-infection model for antifungal screening in vivo. J Antimicrob Chemother 22: 353–358PubMedCrossRefGoogle Scholar
  39. Ryley JF, Rathmell WG (1984) Discovery of antifungal agents: in vitro and in vivo testing. In: Trinci APJ, Ryley JF (eds) Mode of action of antifungal agents. Cambridge University Press, Cambridge, pp 63–87 (Br Mycol Soc Symp No 9 )Google Scholar
  40. Ryley JF, Wilson RG, Gravestock MB, Poyser JP (1981) Experimental approaches to antifungal chemotherapy. Adv Pharmacol Chemother 18: 49–176PubMedCrossRefGoogle Scholar
  41. Ryley JF, McGregor S, Lister SC, Jackson KP (1988a) Kidney function in experimental systemic candidosis of mice. Mycoses 31: 203–207PubMedCrossRefGoogle Scholar
  42. Ryley JF, McGregor S, Wilson RG (1988b) The activity of ICI 195,739, a novel orally active bistriazole, in rodent models of fungal and protozoal infection. Ann N Y Acad Sei 544: 310–328CrossRefGoogle Scholar
  43. Savani DV, Perfect JR, Cobo LM, Durack DT (1987) Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother 31: 6–10PubMedGoogle Scholar
  44. Schaude M, Meingassner JG (1986) A diffusion chamber technique for testing of antifungal drugs against Sporothrix schenckii in vivo. J Med Vet Mycol 24: 297–304PubMedCrossRefGoogle Scholar
  45. Scholer HJ (1960) Experimentelle Vaginal-Candidiasis der Ratte. Path Microbiol 23: 62–68Google Scholar
  46. Shakir BS, Martin MV, Smith CJ (1981) Induced palatal candidosis in the Wistar rat. Arch Oral Biol 26: 787–793PubMedCrossRefGoogle Scholar
  47. Troke PF (1987) Efficacy of fluconazole in animal models of superficial and opportunistic systemic fungal infection. In: Fromtling RA (ed) Recent trends in the discovery, development and evaluation of antifungal agents. J R Prous, Barcelona, pp 103–112Google Scholar
  48. Ueda AK, Franco M, Fabio SA, Prestes FR (1987) Ketoconazole in the treatment of experimental murine paracoccidioidomycosis. Mycopathologia 98: 27–34PubMedCrossRefGoogle Scholar
  49. Van Cutsem J, Janssen PAJ (1984) Experimental systemic dermatophytosis. J Invest Dermatol 83: 26–31PubMedCrossRefGoogle Scholar
  50. Van Cutsem J, Thienpont D (1971) Experimental cutaneous Candida albicans infection in guinea pigs. Sabouraudia 9: 17–20PubMedCrossRefGoogle Scholar
  51. Van Cutsem JM, Thienpont D (1972) Miconazole, a broad-spectrum antimycotic agent with antibacterial activity. Chemotherapy 17: 392–404PubMedCrossRefGoogle Scholar
  52. Van Cutsem J, Fransen J, Van Gerven F, Janssen PAJ (1985) Oral treatment with ketoconazole in systemic candidosis of guineapigs: microbiology, hematology and histopathology. Sabouraudia: J Med Vet Mycol 23: 189–198CrossRefGoogle Scholar
  53. Van Cutsem J., Fransen J, Van Gerven F, Janssen PAJ (1986) Experimental cryptococcosis: dissemination of Cryptococcus neoformans and dermotropism in guineapigs. Mykosen 29: 561–575PubMedGoogle Scholar
  54. Van Cutsem J, Van Gerven J, Janssen PAJ (1987) Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis 9: S15–S32PubMedCrossRefGoogle Scholar
  55. Van Cutsem J, Fransen J, Janssen PAJ (1988) Experimental zygomycosis due to Rhizopus spp. infection by various routes in guineapigs, rats and mice. Mycoses 31: 563–578PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • John F. Ryley

There are no affiliations available

Personalised recommendations